Dr. Calvet had a research grant from the Hospital Clinic i Provincial of Barcelona.
Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients
Article first published online: 6 DEC 2005
Copyright © 1990 American Association for the Study of Liver Diseases
Volume 12, Issue 4, pages 753–760, October 1990
How to Cite
Calvet, X., Bruix, J., Ginés, P., Bru, C., Sole, M., Vilana, R. and Rodés, J. (1990), Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients. Hepatology, 12: 753–760. doi: 10.1002/hep.1840120422
- Issue published online: 6 DEC 2005
- Article first published online: 6 DEC 2005
- Manuscript Accepted: 21 MAY 1990
- Manuscript Received: 5 DEC 1989
- Fundació Catalana per a L'Estudi de les Malalties del Fetge
To investigate the prognostic factors in Western patients with hepatocellular carcinoma, 206 patients with confirmed diagnoses of hepatocellular carcinoma were studied in terms of survival. All patients were diagnosed between 1983 and 1987. A multivariate survival analysis (Cox regression model) using clinical, biochemical, ultrasonographical and pathological data obtained at diagnosis disclosed that bilirubin (p = 0.0001), ascites (p = 0.0001), toxic syndrome (defined by the presence of weight loss > 10% premorbid weight, malaise and anorexia) (p = 0.009), blood urea nitrogen (p = 0.025), tumor size (p = 0.001), γ-glutamyltranspeptidase (p = 0.0006), age (p = 0.0005), serum sodium (p = 0.003) and presence of metastases (p = 0.002) were independent predictors of survival. According to the contribution of each of these factors to the final model, a prognostic index was constructed allowing division of patients in different groups according to their relative risk of death: RRD = EXP (Age × 0.03 + Ascites × 0.8281 + BUN × 0.0137 + Serum sodium × (− 0.0538) + γ-Glutamyltranspeptidase × 0.0019 + Bilirubin × 0.0734 + Tumor size × 0.33 + Toxic syndrome × 0.4965 + Metastases × 0.55).
These results facilitate the stratification of hepatocellular carcinoma patients to design and evaluate future controlled trials. (HEPATOLOGY 1990;12:753–760).